Skip to main content

Table 3 Safety profile according to treatment groups

From: Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial

Adverse events

Intervention arm SPAZ (N = 496) n (%)

Control arm SP (N = 496) n (%)

p-valuea

Total events reported

152 (30.6)

176 (35.5)

0.12

Serious AEs

67 (13.5)

83 (16.7)

0.18

Non-serious AEs

85 (17.1)

93 (18.8)

0.56

Detailed AEs

 Serious events

  Eclampsia

2 (0.4)

1 (0.2)

0.47

  Severe malaria

10 (2.0)

14 (2.8)

0.41

  Preterm birth

23 (4.6)

20 (4.0)

0.75

  Stillbirth

7 (1.4)

11 (2.2)

0.75

  Miscarriage

3 (0.6)

4 (0.8)

0.70

  Emergency cesarean section

7 (2.2)

10 (3.6)

0.26

  Severe anemia

0 (0.0)

2 (0.4)

0.16

  Fetal distress

5 (1.0)

4 (0.8)

0.81

  Neonatal death

5 (1.0)

4 (0.8)

0.73

  Premature rupture of membrane

3 (0.6)

6 (1.6)

0.13

  Neonatal resuscitation

1 (0.2)

3 (0.6)

0.31

  Neonatal distress

1 (0.2)

3 (0.6)

0.31

  Laparoschisis

0 (0.0)

1 (0.2)

0.32

  Non-serious AEs

  Threat preterm birth

1 (0.2)

2 (0.2)

0.56

  Abdominal pain

10 (2.0)

5 (1.0)

0.20

  Cervix infection

0 (0.0)

3 (0.6)

0.08

  Endometritis

0 (0.0)

2 (0.4)

0.16

  False labor

4 (0.8)

6 (1.2)

0.52

  Gastroenteritis

5 (1.0)

8 (1.6)

0.40

  Headache

3 (0.6)

5 (1.0)

0.47

  Uncomplicated malaria

7 (1.4)

9 (1.8)

0.61

  Neonatal infection

4 (0.8)

6 (1.2)

0.52

  Oligo-amnios

2 (0.4)

3 (0.2)

0.56

  Pelvic pain

5 (1.0)

3 (0.6)

0.48

  Pelvic spasm

5 (1.0)

9 (1.8)

0.42

  Pneumonia

5 (1.0)

7 (1.4)

0.56

  Preeclampsia

5 (1.0)

6 (1.2)

0.76

  Urinary infection

1 (0.2)

3 (0.6)

0.18

  Others

17 (3.4)

11 (2.2)

0.34

  1. Others included cough, epigastralgia, nausea, oral mycosis, respiratory distress
  2. AEs adverse events, SP Sulfadoxine-pyrimethamine, SPAZ SP + azithromycin
  3. achi-square or fisher exact test used for comparison